This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Nicox NCX 470 China Regulatory Feedback
Business regulatory feedback

Nicox NCX 470 China Regulatory Feedback

Analysis based on 7 articles · First reported Jun 18, 2026 · Last updated Jun 18, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive regulatory feedback for NCX 470 in China and the anticipated NDA submissions in China and the United States are expected to positively impact NicOx's stock price due to potential future royalties and milestone payments. This also signals progress for Paragon Therapeutics and Kowa (company) in bringing the drug to market, which could benefit their respective businesses.

pharmaceuticals biotechnology
Event Summary

NicOx announced that its exclusive licensee in China, Paragon Therapeutics, received positive pre-submission regulatory feedback from the United States — Center for Drug Evaluation and Research for NCX 470. This feedback is sufficient for Paragon Therapeutics to proceed with the New Drug Application (NDA) submission in China for NCX 470, a novel eye drop for lowering intraocular pressure. This submission is expected to follow shortly after the NCX 470 NDA to the United States — Food and Drug Administration in the United States by NicOx's U.S. partner, Kowa (company), which is anticipated in summer 2026. NicOx stands to receive regulatory and sales milestones, as well as royalties on worldwide sales of NCX 470.

Entities Involved
stock
NicOx
NicOx, an international ophthalmology company, announced positive regulatory feedback for its drug NCX 470 in China, which is expected to lead to a New Drug Application submission. This development is positive for NicOx as it could lead to future royalties and milestone payments.
Importance 100.0 Sentiment 70.0
oth
NCX 470
NCX 470 is a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure. The positive regulatory feedback in China and anticipated NDA submission in the U.S. are significant steps towards its commercialization.
Importance 100.0 Sentiment 70.0
priv
Paragon Therapeutics
Paragon Therapeutics, NicOx's exclusive licensee in China, received positive pre-submission regulatory feedback for NCX 470, allowing them to proceed with the New Drug Application submission in China. This is a significant step towards commercializing the drug in their licensed territories.
Importance 90.0 Sentiment 60.0
priv
Kowa (company)
Kowa (company) is NicOx's exclusive U.S. partner for NCX 470 and is expected to submit the New Drug Application for the drug in the U.S. in summer 2026. Kowa (company) bears the commercialization costs for its licensed territories.
Importance 70.0 Sentiment 60.0
govactor
United States — Center for Drug Evaluation and Research
The United States — Center for Drug Evaluation and Research provided positive pre-submission regulatory feedback for NCX 470, which is crucial for the drug's approval process in China.
Importance 50.0 Sentiment 0.0
per
Doug Hubatsch
Doug Hubatsch, Chief Scientific Officer of NicOx, expressed confidence in the upcoming NDA submissions for NCX 470 in both the U.S. and China.
Importance 20.0 Sentiment 0.0
loc
Southeast Asia
Southeast Asia is one of the markets where NCX 470 is licensed to Paragon Therapeutics.
Importance 10.0 Sentiment 0.0
cnt
Japan
Japan is where the NCX 470 Phase 3 clinical program was initiated in summer 2025.
Importance 10.0 Sentiment 0.0
cnt
South Korea
South Korea is one of the markets where NCX 470 is licensed to Paragon Therapeutics.
Importance 10.0 Sentiment 0.0
stock
Glaukos Corporation
Glaukos Corporation is collaborating with NicOx on a preclinical research program for NCX 1728.
Importance 5.0 Sentiment 0.0
stock
Harrow, Inc.
Harrow, Inc. is a licensee for NicOx's product ZERVIATE in the U.S.
Importance 5.0 Sentiment 0.0
subs
Bausch Health — Bausch & Lomb
Bausch + Lomb is the exclusive worldwide licensee for NicOx's first product, VYZULTA.
Importance 5.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
cnt
China
Importance 0.0 Sentiment 0.0
Relationships
Japan strategic-partner ↔ South Korea Japan views South Korea as a vital regional security and economic partner, engaging in shuttle diplomacy and trilateral
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.